<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36980274</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>18</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Differences in Cerebral Glucose Metabolism in ALS Patients with and without <i>C9orf72</i> and <i>SOD1</i> Mutations.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">933</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells12060933</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is characterized by progressive loss of upper and lower motor neurons. In 10% of patients, the disorder runs in the family. Our aim was to study the impact of ALS-causing gene mutations on cerebral glucose metabolism. Between October 2010 and October 2022, 538 patients underwent genetic testing for mutations with strong evidence of causality for ALS and <sup>18</sup>F-2-fluoro-2-deoxy-D-glucose-PET (FDG PET), at University Hospitals Leuven. We identified 48 <i>C9orf72</i>-ALS and 22 <i>SOD1</i>-ALS patients. After propensity score matching, two cohorts of 48 and 21 matched sporadic ALS patients, as well as 20 healthy controls were included. FDG PET images were assessed using a voxel-based and volume-of-interest approach. We observed widespread frontotemporal involvement in all ALS groups, in comparison to healthy controls. The degree of relative glucose metabolism in <i>SOD1</i>-ALS in motor and extra-motor regions did not differ significantly from matched sporadic ALS patients. In <i>C9orf72</i>-ALS, we found more pronounced hypometabolism in the peri-rolandic region and thalamus, and hypermetabolism in the medulla extending to the pons, in comparison to matched sporadic ALS patients. Our study revealed <i>C9orf72</i>-dependent differences in glucose metabolism in the peri-rolandic region, thalamus, and brainstem (i.e., medulla, extending to the pons) in relation to matched sporadic ALS patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Vocht</LastName><ForeName>Joke</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4116-192X</Identifier><AffiliationInfo><Affiliation>Division of Psychiatry, Division of Neurology, University Hospitals Leuven, VIB-KULeuven Center for Brain &amp; Disease Research, Laboratory of Neurobiology, Department of Neurosciences, Leuven Brain Institute (LBI), Katholieke Universiteit Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Weehaeghe</LastName><ForeName>Donatienne</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-6646-106X</Identifier><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, Ghent University Hospital, 9000 Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ombelet</LastName><ForeName>Fouke</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-1530-0869</Identifier><AffiliationInfo><Affiliation>Division of Neurology, University Hospitals Leuven, VIB-KULeuven Center for Brain &amp; Disease Research, Laboratory of Neurobiology, Department of Neurosciences, Leuven Brain Institute (LBI), Katholieke Universiteit Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masrori</LastName><ForeName>Pegah</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Neurology, University Hospitals Leuven, VIB-KULeuven Center for Brain &amp; Disease Research, Laboratory of Neurobiology, Department of Neurosciences, Leuven Brain Institute (LBI), Katholieke Universiteit Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamaire</LastName><ForeName>Nikita</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Neurology, University Hospitals Leuven, VIB-KULeuven Center for Brain &amp; Disease Research, Laboratory of Neurobiology, Department of Neurosciences, Leuven Brain Institute (LBI), Katholieke Universiteit Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devrome</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Imaging and Pathology, Nuclear Medicine and Molecular Imaging, Katholieke Universiteit Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Esch</LastName><ForeName>Hilde</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-9604-5726</Identifier><AffiliationInfo><Affiliation>Center for Human Genetics, University Hospitals Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moisse</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain &amp; Disease Research, Laboratory of Neurobiology, Department of Neurosciences, Leuven Brain Institute (LBI), Katholieke Universiteit Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koole</LastName><ForeName>Michel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5862-640X</Identifier><AffiliationInfo><Affiliation>Department of Imaging and Pathology, Nuclear Medicine and Molecular Imaging, Katholieke Universiteit Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dupont</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratory of Cognitive Neurology, Department of Neurosciences, Leuven Brain Institute (LBI), Katholieke Universiteit Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Laere</LastName><ForeName>Koen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Imaging and Pathology, Nuclear Medicine and Molecular Imaging, Katholieke Universiteit Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4010-2357</Identifier><AffiliationInfo><Affiliation>Division of Neurology, University Hospitals Leuven, VIB-KULeuven Center for Brain &amp; Disease Research, Laboratory of Neurobiology, Department of Neurosciences, Leuven Brain Institute (LBI), Katholieke Universiteit Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C531617">Amyotrophic lateral sclerosis 1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="Y">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="Y">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="Y">Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">FDG PET</Keyword><Keyword MajorTopicYN="N">SOD1</Keyword><Keyword MajorTopicYN="N">genetic ALS</Keyword></KeywordList><CoiStatement>P.V.D. has served in advisory boards for Biogen, CSL Behring, Alexion Pharmaceuticals, Ferrer, QurAlis, Cytokinetics, Argenx, UCB, Muna Therapeutics, Alector, Augustine Therapeutics, VectorY, Zambon (paid to institution). The other authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>29</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36980274</ArticleId><ArticleId IdType="pmc">PMC10047407</ArticleId><ArticleId IdType="doi">10.3390/cells12060933</ArticleId><ArticleId IdType="pii">cells12060933</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Van Es M.A., Hardiman O., Chio A., Al-Chalabi A., Pasterkamp R.J., Veldink J.H., Van Den Berg L.H. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Masrori P., Van Damme P. Amyotrophic lateral sclerosis: A clinical review. Eur. J. Neurol. 2020;27:1918&#x2013;1929. doi: 10.1111/ene.14393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14393</ArticleId><ArticleId IdType="pmc">PMC7540334</ArticleId><ArticleId IdType="pubmed">32526057</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A.E., Majounie E., Waite A., Sim&#xf3;n-S&#xe1;nchez J., Rollinson S., Gibbs J.R., Schymick J.C., Laaksovirta H., van Swieten J.C., Myllykangas L., et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J., Kirby J., Highley R., Shaw P.J. The Spectrum of C9orf72-mediated Neurodegeneration and Amyotrophic Lateral Sclerosis. Neurotherapeutics. 2015;12:326&#x2013;339. doi: 10.1007/s13311-015-0342-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-015-0342-1</ArticleId><ArticleId IdType="pmc">PMC4404438</ArticleId><ArticleId IdType="pubmed">25731823</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J., Shaw P.J., Kirby J. The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype. Acta Neuropathol. 2014;127:333&#x2013;345. doi: 10.1007/s00401-014-1251-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1251-9</ArticleId><ArticleId IdType="pmc">PMC3925297</ArticleId><ArticleId IdType="pubmed">24493408</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden J.S., Rollinson S., Thompson J.C., Harris J.M., Stopford C.L., Richardson A.M., Jones M., Gerhard A., Davidson Y.S., Robinson A., et al. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Pt 3Brain. 2012;135:693&#x2013;708. doi: 10.1093/brain/awr355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr355</ArticleId><ArticleId IdType="pmc">PMC3286329</ArticleId><ArticleId IdType="pubmed">22300873</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B., Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2014;10:661&#x2013;670. doi: 10.1038/nrneurol.2014.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.184</ArticleId><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O&#x2019;Regan J.P., Deng H.X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R., Flynn L.L., Pitout I.L., Fletcher S., Wilton S.D., Akkari P.A. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front. Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen P.M., Forsgren L., Binzer M., Nilsson P., Ala-Hurula V., Ker&#xe4;nen M.L., Bergmark L., Saarinen A., Haltia T., Tarvainen I., et al. Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients. Pt 4Brain. 1996;119:1153&#x2013;1172. doi: 10.1093/brain/119.4.1153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/119.4.1153</ArticleId><ArticleId IdType="pubmed">8813280</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H.F., Wu Z.Y. Genotype-phenotype correlations of amyotrophic lateral sclerosis. Transl. Neurodegener. 2016;5:3. doi: 10.1186/s40035-016-0050-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-016-0050-8</ArticleId><ArticleId IdType="pmc">PMC4738789</ArticleId><ArticleId IdType="pubmed">26843957</ArticleId></ArticleIdList></Reference><Reference><Citation>Juneja T., Pericak-Vance M.A., Laing N.G., Dave S., Siddique T. Prognosis in familial amyotrophic lateral sclerosis: Progression and survival in patients with glu100gly and ala4val mutations in Cu,Zn superoxide dismutase. Neurology. 1997;48:55&#x2013;57. doi: 10.1212/WNL.48.1.55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.48.1.55</ArticleId><ArticleId IdType="pubmed">9008494</ArticleId></ArticleIdList></Reference><Reference><Citation>Millecamps S., Salachas F., Cazeneuve C., Gordon P., Bricka B., Camuzat A., Guillot-No&#xeb;l L., Russaouen O., Bruneteau G., Pradat P.F., et al. SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: Genotype-phenotype correlations. J. Med. Genet. 2010;47:554&#x2013;560. doi: 10.1136/jmg.2010.077180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmg.2010.077180</ArticleId><ArticleId IdType="pubmed">20577002</ArticleId></ArticleIdList></Reference><Reference><Citation>Project MinE: Study design and pilot analyses of a large-scale whole-genome sequencing study in amyotrophic lateral sclerosis. Eur. J. Hum. Genet. 2018;26:1537&#x2013;1546. doi: 10.1038/s41431-018-0177-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41431-018-0177-4</ArticleId><ArticleId IdType="pmc">PMC6138692</ArticleId><ArticleId IdType="pubmed">29955173</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita S., Ando Y. Genotype-phenotype relationship in hereditary amyotrophic lateral sclerosis. Transl. Neurodegener. 2015;4:13. doi: 10.1186/s40035-015-0036-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-015-0036-y</ArticleId><ArticleId IdType="pmc">PMC4513711</ArticleId><ArticleId IdType="pubmed">26213621</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis S., Goizet C., Soulages A., Vallat J.M., Masson G.L. Genetics of amyotrophic lateral sclerosis: A review. J. Neurol. Sci. 2019;399:217&#x2013;226. doi: 10.1016/j.jns.2019.02.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.02.030</ArticleId><ArticleId IdType="pubmed">30870681</ArticleId></ArticleIdList></Reference><Reference><Citation>Bella E.D., Bersano E., Bruzzone M.G., Gellera C., Pensato V., Lauria G., Consonni M. Behavioral and Cognitive Phenotypes of Patients With Amyotrophic Lateral Sclerosis Carrying SOD1 Variants. Neurology. 2022;99:e2052&#x2013;e2062. doi: 10.1212/WNL.0000000000201044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000201044</ArticleId><ArticleId IdType="pmc">PMC9651465</ArticleId><ArticleId IdType="pubmed">35985819</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojsi F., Siciliano M., Femiano C., Santangelo G., Lunetta C., Calvo A., Moglia C., Marinou K., Ticozzi N., Drago Ferrante G., et al. Comorbidity of dementia with amyotrophic lateral sclerosis (ALS): Insights from a large multicenter Italian cohort. J. Neurol. 2017;264:2224&#x2013;2231. doi: 10.1007/s00415-017-8619-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-017-8619-4</ArticleId><ArticleId IdType="pubmed">28914354</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S., Rouleau G.A., Kabashi E. TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: Summary and update. Hum. Mutat. 2013;34:812&#x2013;826. doi: 10.1002/humu.22319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22319</ArticleId><ArticleId IdType="pubmed">23559573</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Laere K., Vanhee A., Verschueren J., De Coster L., Driesen A., Dupont P., Robberecht W., Van Damme P. Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: A prospective study. JAMA Neurol. 2014;71:553&#x2013;561. doi: 10.1001/jamaneurol.2014.62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.62</ArticleId><ArticleId IdType="pubmed">24615479</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Weehaeghe D., Devrome M., Schramm G., De Vocht J., Deckers W., Baete K., Van Damme P., Koole M., Van Laere K. Combined brain and spinal FDG PET allows differentiation between ALS and ALS mimics. Eur. J. Nucl. Med. Mol. Imaging. 2020;47:2681&#x2013;2690. doi: 10.1007/s00259-020-04786-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-020-04786-y</ArticleId><ArticleId IdType="pubmed">32314027</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Weehaeghe D., Ceccarini J., Delva A., Robberecht W., Van Damme P., Van Laere K. Prospective Validation of 18F-FDG Brain PET Discriminant Analysis Methods in the Diagnosis of Amyotrophic Lateral Sclerosis. J. Nucl. Med. 2016;57:1238&#x2013;1243. doi: 10.2967/jnumed.115.166272.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.115.166272</ArticleId><ArticleId IdType="pubmed">26940764</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagani M., Chi&#xf2; A., Valentini M.C., &#xd6;berg J., Nobili F., Calvo A., Moglia C., Bertuzzo D., Morbelli S., De Carli F., et al. Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology. 2014;83:1067&#x2013;1074. doi: 10.1212/WNL.0000000000000792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000792</ArticleId><ArticleId IdType="pubmed">25122207</ArticleId></ArticleIdList></Reference><Reference><Citation>Canosa A., Pagani M., Cistaro A., Montuschi A., Iazzolino B., Fania P., Cammarosano S., Ilardi A., Moglia C., Calvo A., et al. 18F-FDG-PET correlates of cognitive impairment in ALS. Neurology. 2016;86:44&#x2013;49. doi: 10.1212/WNL.0000000000002242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002242</ArticleId><ArticleId IdType="pubmed">26590270</ArticleId></ArticleIdList></Reference><Reference><Citation>Cistaro A., Pagani M., Montuschi A., Calvo A., Moglia C., Canosa A., Restagno G., Brunetti M., Traynor B.J., Nobili F., et al. The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients. Eur. J. Nucl. Med. Mol. Imaging. 2014;41:844&#x2013;852. doi: 10.1007/s00259-013-2667-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-013-2667-5</ArticleId><ArticleId IdType="pmc">PMC8957062</ArticleId><ArticleId IdType="pubmed">24445987</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;necker S., Neuhofer C., Otto M., Ludolph A., Kassubek J., Landwehrmeyer B., Anderl-Straub S., Semler E., Diehl-Schmid J., Prix C., et al. Atrophy in the Thalamus But Not Cerebellum Is Specific for C9orf72 FTD and ALS Patients&#x2014;An Atlas-Based Volumetric MRI Study. Front. Aging Neurosci. 2018;10:45. doi: 10.3389/fnagi.2018.00045.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2018.00045</ArticleId><ArticleId IdType="pmc">PMC5863593</ArticleId><ArticleId IdType="pubmed">29599716</ArticleId></ArticleIdList></Reference><Reference><Citation>Diehl-Schmid J., Licata A., Goldhardt O., F&#xf6;rstl H., Yakushew I., Otto M., Anderl-Straub S., Beer A., Ludolph A.C., Landwehrmeyer G.B., et al. FDG-PET underscores the key role of the thalamus in frontotemporal lobar degeneration caused by C9ORF72 mutations. Transl. Psychiatry. 2019;9:54. doi: 10.1038/s41398-019-0381-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-019-0381-1</ArticleId><ArticleId IdType="pmc">PMC6355852</ArticleId><ArticleId IdType="pubmed">30705258</ArticleId></ArticleIdList></Reference><Reference><Citation>Canosa A., Calvo A., Moglia C., Vasta R., Palumbo F., Solero L., Di Pede F., Cabras S., Arena V., Zocco G., et al. Amyotrophic lateral sclerosis with SOD1 mutations shows distinct brain metabolic changes. Eur. J. Nucl. Med. Mol. Imaging. 2022;49:2242&#x2013;2250. doi: 10.1007/s00259-021-05668-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05668-7</ArticleId><ArticleId IdType="pmc">PMC9165265</ArticleId><ArticleId IdType="pubmed">35076740</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrooten M., Smetcoren C., Robberecht W., Van Damme P. Benefit of the Awaji diagnostic algorithm for amyotrophic lateral sclerosis: A prospective study. Ann. Neurol. 2011;70:79&#x2013;83. doi: 10.1002/ana.22380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22380</ArticleId><ArticleId IdType="pubmed">21437935</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum P.R., Rubin D.B. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41&#x2013;55. doi: 10.1093/biomet/70.1.41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/70.1.41</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Agostino R.B., Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat. Med. 1998;17:2265&#x2013;2281. doi: 10.1002/(SICI)1097-0258(19981015)17:19&lt;2265::AID-SIM918&gt;3.0.CO;2-B.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0258(19981015)17:19&lt;2265::AID-SIM918&gt;3.0.CO;2-B</ArticleId><ArticleId IdType="pubmed">9802183</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum J.M., Stambler N., Malta E., Fuller C., Hilt D., Thurmond B., Nakanishi A. The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III) J. Neurol. Sci. 1999;169:13&#x2013;21. doi: 10.1016/S0022-510X(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., Mazoyer B., Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273&#x2013;289. doi: 10.1006/nimg.2001.0978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nimg.2001.0978</ArticleId><ArticleId IdType="pubmed">11771995</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolls E.T., Huang C.C., Lin C.P., Feng J., Joliot M. Automated anatomical labelling atlas 3. Neuroimage. 2020;206:116189. doi: 10.1016/j.neuroimage.2019.116189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2019.116189</ArticleId><ArticleId IdType="pubmed">31521825</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y., Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J. R. Stat. Society. Ser. B. 1995;57:289&#x2013;300. doi: 10.1111/j.2517-6161.1995.tb02031.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2517-6161.1995.tb02031.x</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vocht J., Blommaert J., Devrome M., Radwan A., Van Weehaeghe D., De Schaepdryver M., Ceccarini J., Rezaei A., Schramm G., van Aalst J., et al. Use of Multimodal Imaging and Clinical Biomarkers in Presymptomatic Carriers of C9orf72 Repeat Expansion. JAMA Neurol. 2020;77:1008&#x2013;1017. doi: 10.1001/jamaneurol.2020.1087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.1087</ArticleId><ArticleId IdType="pmc">PMC7417970</ArticleId><ArticleId IdType="pubmed">32421156</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr A., Sattler R. Synaptic dysfunction and altered excitability in C9ORF72 ALS/FTD. Brain Res. 2018;1693 Pt A:98&#x2013;108. doi: 10.1016/j.brainres.2018.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2018.02.011</ArticleId><ArticleId IdType="pmc">PMC5997509</ArticleId><ArticleId IdType="pubmed">29453960</ArticleId></ArticleIdList></Reference><Reference><Citation>Henstridge C.M., Tzioras M., Paolicelli R.C. Glial Contribution to Excitatory and Inhibitory Synapse Loss in Neurodegeneration. Front. Cell. Neurosci. 2019;13:63. doi: 10.3389/fncel.2019.00063.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2019.00063</ArticleId><ArticleId IdType="pmc">PMC6399113</ArticleId><ArticleId IdType="pubmed">30863284</ArticleId></ArticleIdList></Reference><Reference><Citation>Cali&#xf3; M.L., Henriques E., Siena A., Bertoncini C.R.A., Gil-Mohapel J., Rosenstock T.R. Mitochondrial Dysfunction, Neurogenesis, and Epigenetics: Putative Implications for Amyotrophic Lateral Sclerosis Neurodegeneration and Treatment. Front. Neurosci. 2020;14:679. doi: 10.3389/fnins.2020.00679.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00679</ArticleId><ArticleId IdType="pmc">PMC7373761</ArticleId><ArticleId IdType="pubmed">32760239</ArticleId></ArticleIdList></Reference><Reference><Citation>Terada T., Therriault J., Kang M.S., Savard M., Pascoal T.A., Lussier F., Tissot C., Wang Y.-T., Benedet A., Poltronetti N.M., et al. Mitochondrial complex I abnormalities underlie neurodegeneration and cognitive decline in Alzheimer&#x2019;s disease. Eur. J. Neurol. 2022;29:1324&#x2013;1334. doi: 10.1111/ene.15246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15246</ArticleId><ArticleId IdType="pubmed">35007366</ArticleId></ArticleIdList></Reference><Reference><Citation>Malpetti M., Holland N., Jones P.S., Ye R., Cope T.E., Fryer T.D., Hong Y.T., Savulich G., Rittman T., Passamonti L., et al. Synaptic density in carriers of C9orf72 mutations: A [11C]UCB-J PET study. Ann. Clin. Transl. Neurol. 2021;8:1515&#x2013;1523. doi: 10.1002/acn3.51407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51407</ArticleId><ArticleId IdType="pmc">PMC8283163</ArticleId><ArticleId IdType="pubmed">34133849</ArticleId></ArticleIdList></Reference><Reference><Citation>Cistaro A., Valentini M.C., Chi&#xf2; A., Nobili F., Calvo A., Moglia C., Montuschi A., Morbelli S., Salmaso D., Fania P., et al. Brain hypermetabolism in amyotrophic lateral sclerosis: A FDG PET study in ALS of spinal and bulbar onset. Eur. J. Nucl. Med. Mol. Imaging. 2012;39:251&#x2013;259. doi: 10.1007/s00259-011-1979-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-011-1979-6</ArticleId><ArticleId IdType="pubmed">22089661</ArticleId></ArticleIdList></Reference><Reference><Citation>Mat&#xed;as-Guiu J.A., Pytel V., Cabrera-Mart&#xed;n M.N., Gal&#xe1;n L., Valles-Salgado M., Guerrero A., Moreno-Ramos T., Mat&#xed;as-Guiu J., Carreras J.L. Amyloid- and FDG-PET imaging in amyotrophic lateral sclerosis. Eur. J. Nucl. Med. Mol. Imaging. 2016;43:2050&#x2013;2060. doi: 10.1007/s00259-016-3434-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-016-3434-1</ArticleId><ArticleId IdType="pubmed">27262702</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J., Toledo J.B., Van Deerlin V.M., Elman L., McCluskey L., Lee V.M., Trojanowski J.Q. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS ONE. 2012;7:e39216. doi: 10.1371/journal.pone.0039216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0039216</ArticleId><ArticleId IdType="pmc">PMC3375234</ArticleId><ArticleId IdType="pubmed">22720079</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew S., Atassi N. Positron Emission Tomography Molecular Imaging Biomarkers for Amyotrophic Lateral Sclerosis. Front. Neurol. 2019;10:135. doi: 10.3389/fneur.2019.00135.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00135</ArticleId><ArticleId IdType="pmc">PMC6405430</ArticleId><ArticleId IdType="pubmed">30881332</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron T.F., Daughrity L.M., Heckman M.G., Diehl N.N., Wuu J., Miller T.M., Pastor P., Trojanowski J.Q., Grossman M., Berry J.D., et al. Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis. Ann. Neurol. 2017;82:139&#x2013;146. doi: 10.1002/ana.24980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24980</ArticleId><ArticleId IdType="pmc">PMC5676468</ArticleId><ArticleId IdType="pubmed">28628244</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin D.J., McMillan C.T., Brettschneider J., Libon D.J., Powers J., Rascovsky K., Toledo J.B., Boller A., Bekisz J., Chandrasekaran K. Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2013;84:163&#x2013;169. doi: 10.1136/jnnp-2012-303507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-303507</ArticleId><ArticleId IdType="pmc">PMC3543474</ArticleId><ArticleId IdType="pubmed">23117491</ArticleId></ArticleIdList></Reference><Reference><Citation>Umoh M.E., Fournier C., Li Y., Polak M., Shaw L., Landers J.E., Hu W., Gearing M., Glass J.D. Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population. Neurology. 2016;87:1024&#x2013;1030. doi: 10.1212/WNL.0000000000003067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003067</ArticleId><ArticleId IdType="pmc">PMC5027809</ArticleId><ArticleId IdType="pubmed">27488601</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanovello M., Sorar&#xf9; G., Campi C., Anglani M., Spimpolo A., Berti S., Buss&#xe8; C., Mozzetta S., Cagnin A., Cecchin D. Brain Stem Glucose Hypermetabolism in Amyotrophic Lateral Sclerosis/Frontotemporal Dementia and Shortened Survival: An 18F-FDG PET/MRI Study. J. Nucl. Med. 2022;63:777&#x2013;784. doi: 10.2967/jnumed.121.262232.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.121.262232</ArticleId><ArticleId IdType="pubmed">34503963</ArticleId></ArticleIdList></Reference><Reference><Citation>Devrome M., Van Weehaeghe D., De Vocht J., Van Damme P., Van Laere K., Koole M. Glucose metabolic brain patterns to discriminate amyotrophic lateral sclerosis from Parkinson plus syndromes. EJNMMI Res. 2018;8:110. doi: 10.1186/s13550-018-0458-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13550-018-0458-5</ArticleId><ArticleId IdType="pmc">PMC6292827</ArticleId><ArticleId IdType="pubmed">30547248</ArticleId></ArticleIdList></Reference><Reference><Citation>van Weehaeghe D., Ceccarini J., Willekens S.M., de Vocht J., van Damme P., van Laere K. Is there a glucose metabolic signature of spreading TDP-43 pathology in amyotrophic lateral sclerosis? Q. J. Nucl. Med. Mol. Imaging. 2020;64:96&#x2013;104. doi: 10.23736/S1824-4785.17.03009-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.23736/S1824-4785.17.03009-6</ArticleId><ArticleId IdType="pubmed">29166751</ArticleId></ArticleIdList></Reference><Reference><Citation>Henstridge C.M., Sideris D.I., Carroll E., Rotariu S., Salomonsson S., Tzioras M., McKenzie C.A., Smith C., von Arnim C.A.F., Ludolph A.C., et al. Synapse loss in the prefrontal cortex is associated with cognitive decline in amyotrophic lateral sclerosis. Acta Neuropathol. 2018;135:213&#x2013;226. doi: 10.1007/s00401-017-1797-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1797-4</ArticleId><ArticleId IdType="pmc">PMC5773656</ArticleId><ArticleId IdType="pubmed">29273900</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi K., Mochizuki Y., Takeuchi R., Shimizu T., Nagao M., Watabe K., Arai N., Oyanagi K., Onodera O., Hayashi M., et al. Clinicopathological characteristics of patients with amyotrophic lateral sclerosis resulting in a totally locked-in state (communication Stage V) Acta Neuropathol. Commun. 2016;4:107. doi: 10.1186/s40478-016-0379-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0379-3</ArticleId><ArticleId IdType="pmc">PMC5045653</ArticleId><ArticleId IdType="pubmed">27716404</ArticleId></ArticleIdList></Reference><Reference><Citation>Agosta F., Spinelli E.G., Marjanovic I.V., Stevic Z., Pagani E., Valsasina P., Salak-Djokic B., Jankovic M., Lavrnic D., Kostic V.S., et al. Unraveling ALS due to SOD1 mutation through the combination of brain and cervical cord MRI. Neurology. 2018;90:e707. doi: 10.1212/WNL.0000000000005002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005002</ArticleId><ArticleId IdType="pubmed">29367447</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Hammers A., Allsop J., Al-chalabi A., Shaw C.E., Brooks D.J., Nigel Leigh P., Andersen P.M. Volumetric cortical loss in sporadic and familial amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2007;8:343&#x2013;347. doi: 10.1080/17482960701538734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960701538734</ArticleId><ArticleId IdType="pubmed">18033592</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Hammers A., Al-Chalabi A., Shaw C.E., Andersen P.M., Brooks D.J., Leigh P.N. Distinct cerebral lesions in sporadic and &#x2018;D90A&#x2019; SOD1 ALS: Studies with [11C]flumazenil PET. Brain. 2005;128:1323&#x2013;1329. doi: 10.1093/brain/awh509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh509</ArticleId><ArticleId IdType="pubmed">15843422</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Rabiner E.A., Al-Chalabi A., Shaw C.E., Brooks D.J., Leigh P.N., Andersen P.M. Cortical 5-HT1A receptor binding in patients with homozygous D90A SOD1 vs sporadic ALS. Neurology. 2007;68:1233&#x2013;1235. doi: 10.1212/01.wnl.0000259083.31837.64.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000259083.31837.64</ArticleId><ArticleId IdType="pubmed">17420412</ArticleId></ArticleIdList></Reference><Reference><Citation>Tondo G., Iaccarino L., Cerami C., Vanoli G.E., Presotto L., Masiello V., Coliva A., Salvi F., Bartolomei I., Mosca L., et al. (11) C-PK11195 PET-based molecular study of microglia activation in SOD1 amyotrophic lateral sclerosis. Ann. Clin. Transl. Neurol. 2020;7:1513&#x2013;1523. doi: 10.1002/acn3.51112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51112</ArticleId><ArticleId IdType="pmc">PMC7480909</ArticleId><ArticleId IdType="pubmed">32762033</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Weehaeghe D., Babu S., De Vocht J., Z&#xfc;rcher N.R., Chew S., Tseng C.J., Loggia M.L., Koole M., Rezaei A., Schramm G., et al. Moving Toward Multicenter Therapeutic Trials in Amyotrophic Lateral Sclerosis: Feasibility of Data Pooling Using Different Translocator Protein PET Radioligands. J. Nucl. Med. 2020;61:1621&#x2013;1627. doi: 10.2967/jnumed.119.241059.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.119.241059</ArticleId><ArticleId IdType="pmc">PMC9364895</ArticleId><ArticleId IdType="pubmed">32169920</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho D.E., Imai K., King G., Stuart E.A. Matching as Nonparametric Preprocessing for Reducing Model Dependence in Parametric Causal Inference. Political Anal. 2007;15:199&#x2013;236. doi: 10.1093/pan/mpl013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pan/mpl013</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>